Sore Throat Clinical Trial
Official title:
A Multicenter, Single-blind, Randomized, Placebo-controlled Comparative Study on Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® Spray and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat in Common Cold
The primary objective of this multicenter, single-blind, randomized, placebo-controlled, prospective, comparative study with parallel design and 4-arms is to evaluate superiority of Lysobact Complete Spray® against placebo and non inferiority of Lysobact Complete Spray® against active comparators (Tantum Verde® and Pharyngal®) in terms of efficacy based on the pain VAS scores evaluated by the patient using Sore Throat Pain Intensity Scale (STPIS).
This study will be conducted in approximately 3 centers in Bosnia Herzegovina and in 4 centers in Turkey. Primary objective: The primary objective of this study is to evaluate superiority of Lysobact Complete Spray® against placebo and non inferiority of Lysobact Complete Spray® against active comparators (Tantum Verde® and Pharyngal®) in terms of efficacy based on the pain VAS scores evaluated by the patient using Sore Throat Pain Intensity Scale (STPIS). Secondary objective(s): - Safety evaluation of Lysobact Complete Spray®, Tantum Verde® Spray, Pharyngal® Oromucosal Spray, based on the frequency and nature of adverse events occurring during treatment period. - Extent of change in difficulty in swallowing, evaluated on the basis of Difficulty in Swallowing Scale (DSS), on Day 2, Day 4 and Day 6, as compared with baseline. - Extent of change in swollen throat evaluation based on Swollen Throat Scale (STS) on Day 2, Day 4 and Day 6, as compared with baseline. - Change in frequency of study treatment applications on Day 2, Day 4 and Day 6, as compared with baseline. Test product: Lysobact Complete Spray® Active comparator product: Tantum Verde® Spray Active comparator product: Pharyngal® Oromucosal Spray Placebo product: Placebo Primary endpoint: • Primary endpoint is the change from baseline to Day 6 in mean VAS score for STPIS. Secondary endpoint(s): Secondary endpoints are as follows: - change from baseline to Day 6 in mean VAS score for DSS - change from baseline to Day 6 in mean VAS score for SwoTS - change from baseline to each visit (Day 2, Day 4, Day 6) for STPIS , DSS and SwoTS - percent improvement from baseline to each visit (Day 2, Day 4, Day 6) for STPIS , DSS and SwoTS - Incidence of adverse events and relationship to the study treatments - Incidence of serious adverse events and relationship to the study treatments Statistical methods: All patients who have received at least one dose of any study medication will be included in the safety evaluation (safety population). Patients who have completed all visits according to the protocol will be included in the efficacy population. The superiority and inferiority of Lysobact Complete Spray® will be tested in hierarchical order by the comparison of the mean change of VAS scores [Sore Throat Pain Intensity Scale (STPIS)] from baseline to Day 2, 4 and 6. Planned treatment duration is 5 days. Safety will be followed-up until Day 6. End of study is defined as the end of the follow up period for the last patient. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04083417 -
Sore Throat in Primary Care - a Comparison of Phenoxymethylpenicillin and no Antibiotic Treatment
|
Phase 4 | |
| Not yet recruiting |
NCT03517215 -
The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program
|
N/A | |
| Not yet recruiting |
NCT01782183 -
Thermographic Characteristics of Sore Throat by Thermographic Camera
|
N/A | |
| Completed |
NCT02608788 -
S.L. Spray Solution® and Difflam® and Acular®Spray for the Prevention of Postoperative Sore Throat
|
Phase 4 | |
| Completed |
NCT01986361 -
Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
|
Phase 3 | |
| Completed |
NCT01118533 -
Impact of Blades Used for Scheduled Orotracheal Intubation on Postoperative Sore Throat
|
N/A | |
| Completed |
NCT03397797 -
Effect of Intraoperative Neuromuscular Blockade on Postoperative Sore Throat and Hoarseness
|
||
| Completed |
NCT01902641 -
Muscle Relaxation for Short Procedures
|
N/A | |
| Completed |
NCT01444703 -
Comparison of Licorice Versus Sugar-water Gargle for Prevention of Postoperative Sore Throat and Postextubation Coughing
|
N/A | |
| Completed |
NCT00957996 -
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
|
Phase 3 | |
| Completed |
NCT01033799 -
Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers
|
N/A | |
| Completed |
NCT05069844 -
Preoperative Gum Chewing for Different Durations to Prevent Sore Throat After Endotracheal Intubation
|
N/A | |
| Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
| Recruiting |
NCT03369132 -
Efficacy of Natural Seawater Based Throat Spray in Acute Sore Throat Relief
|
N/A | |
| Completed |
NCT02682134 -
Sore Throat Prevention Following Intubation
|
Phase 4 | |
| Terminated |
NCT00958776 -
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
|
Phase 3 | |
| Completed |
NCT00242281 -
APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat
|
Phase 3 | |
| Completed |
NCT03729973 -
Comparing Efficacy Preoperative Nebulized: Ketamine , Mgspo4 ,and Lidocaine In Attenuating Endotracheal Sore Throat
|
Phase 3 | |
| Completed |
NCT04085744 -
A Comparison Of Local Anesthetic Agents And Steroid On Tracheal Tube Cuff
|
N/A | |
| Completed |
NCT01506583 -
Clinical Evaluation of QFlu Combo Test
|